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Abstract
Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of
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Jewish Hospital. We identified all adult HLH patients with at least 2 ferritin levels

factors for overall survival; factors predicting early mortality have not been suffiMethods: This was a collaborative study between Henry Ford Hospital and Barnes-
within 30 days from admission.
Results: One-hundred twenty-four patients were identified. There were 77 males and
47 females; the median age at diagnosis was 48 years. Multivariate analysis showed
that age (OR = 11.41; 95% CI:2.71-48.04; P = .001), hepatomegaly (OR = 15.68; 95%
CI:3.24-75.96; P = .001), hyponatremia (OR = 5.94; 95% CI:1.76-20.1; P = .004), hypoalbuminemia (OR = 7.47; 95% CI:2.08-26.85; P = .002), and increasing ferritin levels
(OR = 19.46; 95% CI:4.69-80.71; P < .001) were significant predictors of 30-day mortality. Patients with declining ferritin by more than 35% from the ferritin peak were
more likely to survive the first 30 days of admission (OR = 4.33; 95% CI:1.04-18.1;
P = .033). By risk stratifying our cohort, we identified changes in ferritin levels to be
the most significant prognostic factor of 30-day mortality among other risk factors.
Further investigating the prognostic utility of ferritin showed that increasing ferritin
during the 1st week of admission (data available for 44 patients) was the only significant predictor of 30-day mortality.
Conclusions: To the best of our knowledge, this is the first study reporting changes
in ferritin to be a predictor for early death in adult HLH. Changes in ferritin might be
a useful indicator of adult HLH disease activity and early prognosis.
KEYWORDS

adult, change, early death, ferritin, hemophagocytic lymphohistiocytosis, predictor

1 | I NTRO D U C TI O N

(acquired). Primary HLH occurs most commonly in infants and young
children and is caused by genetic defects in proteins involved in the

Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome

function of T lymphocytes and natural killer (NK) cells.3 On the other

of pathologic immune activation resulting in hyper-
inflammatory

hand, secondary HLH typically occurs in adults and is often triggered

response.1,2 HLH can be either primary (familial) or secondary

by infections the most recent of which is COVID-19,4 malignancies,
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autoimmune diseases, acquired immune deficiency, as well as im5

decreasing after peak ferritin). Patients who were clinically managed

mune suppression and hematopoietic stem cell transplantation. In

as HLH, but did not meet the HLH-2004 criteria, were not included

some cases, the initiating cause of HLH is not identified.

in the study. We determined the most likely trigger of secondary

The common clinical and laboratory features of HLH are fever,

HLH (malignancy, infection, autoimmune, and idiopathic) based on

hepatosplenomegaly, cytopenias, hyperferritinemia, and hypertri-

treating physician's assessment or evidence we retrieved from the

glyceridemia accompanied with or without hypofibrinogenemia.

6

medical record.

Hemophagocytosis involving the bone marrow, liver, or any part
of the reticuloendothelial system is characteristic, though not specific for HLH.7 The Histiocyte Society published the first diagnostic
8

2.2 | Data collection

9

guidelines for HLH in 1991 and revised them in 2004. Although
these criteria were initially applied to pediatric HLH, they are also

We reviewed all available electronic medical records including pa-

used to diagnose adult HLH.

tients’ charts, laboratory, and pathology reports. We collected de-

HLH can affect patients of all ages. Diagnosis of HLH is challeng-

mographic information, medical history and underlying diseases,

ing for physicians, and it may be delayed. The clinical and labora-

clinical presentation, and laboratory results, treatments, and sur-

tory findings in HLH resemble presentations of some of the diseases

vival. We screened medical records for information on immuno-

that trigger the pathologic immune response.10 Often HLH mimics

suppression, organ damage including hepatomegaly, transaminitis

severe sepsis, multiorgan dysfunction syndrome (MODS), and sys-

(aspartate transaminase (AST) and/or alanine transaminase (ALT)

11,12

temic inflammatory response syndrome (SIRS).

HLH has a dis-

levels above the normal reference range), hypoalbuminemia, renal

mal outcome, and fatality rate is high during the first few weeks due

insufficiency (serum creatinine level above the normal reference

to end-organ damage.13 Most studies of adult HLH have evaluated

range), coagulopathy (defined as prolonged prothrombin time (PT)

prognostic factors for overall survival; factors predicting early mor-

and/or prolonged activated partial thromboplastin time (aPTT)), and

tality have not been extensively investigated. We retrospectively

hypofibrinogenemia (≤150 mg/dL). Analyses of laboratory values

studied 124 patients to determine the possible risk factors of early

were based on reference ranges at each institution.

death in adult HLH. We hypothesized that changes in ferritin are
associated with risk of early mortality in adult HLH.

2 | M ATE R I A L A N D M E TH O DS
2.1 | Patients

2.3 | Statistical methods
Results were presented as median plus range, or percentages as indicated. In the univariate analysis, the independent two-sample t test
for continuous data and Pearson's chi-square test or Fisher's exact
test for categorical data were used to determine the significance and

This was a collaborative study between Henry Ford Hospital

odds ratio (OR) for the independent clinical and laboratory variables

(Detroit, Michigan) and Barnes-Jewish Hospital (St. Louis, Missouri).

as related to 30-day mortality. Thirty-day mortality was defined as

The Institutional Review Boards (IRB) of both institutions approved

death from any cause within 30 days of admission. Ferritin values

these retrospective chart review studies and waived the require-

within 30 days of admission were used to determine whether the

ment for written informed consent. All adult patients (≥18 years)

ferritin trend was decreasing or increasing in relation to peak fer-

with a diagnosis of HLH were identified at Barnes-Jewish Hospital

ritin. A multivariate analysis was performed using logistic regression

from October 2003 through June 2017, and at Henry Ford Hospital

to identify the risk factors for early mortality. A backward stepwise

from April 2010 through December 2019. A diagnosis of HLH was es-

(Wald) selection model was performed, with significance level for

tablished based on the 2004 Histiocyte Society Criteria (HLH-2004)

removal from the model set at 0.1. The method of Kaplan-Meier was

which requires five of the following eight criteria: (a) fever ≥ 38.5°C;

used to plot survival curves and estimate survival probabilities. Log-

(b) splenomegaly; (c) cytopenias of two or three cell lines: absolute

rank test was used to compare the survival curves between groups.

neutrophil count (ANC) <1 × 109/L, hemoglobin < 9 g/dL, platelet

All tests of significance were two-sided, and a P value of <.05 was

count < 100×109/L; (d) serum triglycerides ≥ 265 mg/dL or fibrinogen ≤ 150 mg/dL; (e) serum ferritin ≥ 500 mcg/L; (f) soluble IL-2

regarded as significant. All statistical analyses were performed using
SPSS software, version 22 (SPSS Inc).

receptor (soluble CD25) ≥2400 U/mL; (g) low/absent NK cell activity; and (h) tissue histology showing hemophagocytosis in the bone
marrow, spleen, lymph nodes, or liver.9 In addition, we included in
the analysis only patients who had at least two ferritin levels within
30 days of admission. Admission ferritin was the initial ferritin, and

3 | R E S U LT S
3.1 | Clinical characteristics and laboratory tests

peak ferritin was the highest ferritin within 30 days after admission.
We classified ferritin changes during admission as increasing (peak

We included 124 adult HLH patients in our analysis who fulfilled the

ferritin being the last ferritin value) or decreasing (ferritin values

inclusion criteria (88 patients from Barnes-Jewish Hospital and 36

|

SHAAR et al.

3

patients from Henry Ford Hospital). The selection of patients for

lupus erythematosus (SLE) was the most common diagnosis among

analysis was based on the algorithm shown in Figure S1. There were

autoimmune-associated HLH cases.

77 males and 47 females; the median age at diagnosis was 48 years

Fever was present in 119 (95.2%) patients with a median maxi-

(range: 18-8 4 years). Ethnicity was distributed as follows: Caucasian

mum temperature of 39.3°C (range: 37.2°C-42.2°C). Splenomegaly

(n = 89, 71.8%), African American (n = 29, 23.4%), and Asian (n = 6,

and hepatomegaly occurred in 89 (71.8%) and 30 (24.2%) patients,

4.8%). The initial characteristics of patients are summarized in

respectively. Most patients were anemic (90.3%) and thrombocyto-

Table 1.

penic (93.5%) at presentation with a median hemoglobin of 8 g/dL

The likely causes or triggers of HLH in our patients were as follows: 45 (36.3%) infections, 43 (34.7%) malignancies, 9 (7.2%) autoimmune disorders, 1 (0.8%) primary immunodeficiency, 2 (1.6%)
postsolid organ transplantation, and 24 (19.4%) idiopathic (Table 2).

(range: 4.1 g/dL-12.6 g/dL) and median platelet count of 43 × 109/L

(range: 6 × 109/L-432 × 109/L). Neutropenia (ANC < 0.5 × 109/L) was
identified in 41 (33.1%) patients with a median ANC of 2.1 × 109/L

(range: 0 × 109/L-52.6 × 109/L). Nearly all patients had an elevated

In the 45 patients with infectious diseases, viral infections were

serum lactate dehydrogenase (LDH) (N = 111/119; 93.3%), and a ma-

the most common cause with 9 (20%) EBV cases and 6 (13.3%)

jority had increased transaminases, triglycerides, and total bilirubin:

HIV cases. Bacterial and fungal infections were identified in 12
and 6 patients, respectively. Among the malignancy-associated
HLH cases, B-
cell lymphoma followed by T-
cell lymphoma and
Hodgkin lymphoma were the most common diagnoses. Systemic

TA B L E 2 Underlying disorders associated with adult HLH
patients (n = 124)
Cause

No. of
patients

Infection, n = 45 (36.3%)

TA B L E 1

Patients’ initial characteristics

EBV

9

HIV

6

Variable

Median (Range)

Hepatitis C virus

2

Age, years

48 (18-8 4)

CMV

1

Gender, no. of patients

77 males, 47 females

Other viruses

Ethnicity, no. of patients (%)

Caucasian 89 (71.8)

Bacterial

African American 29 (23.4)

Fungal

9
12

Asian 6 (4.8)

Histoplasmosis

3

Splenomegaly, no. of patients (%)

89 (71.8%)

Candidemia

1

Hepatomegaly, no. of patients (%)

30 (24.2%)

Coccidiomycosis

1

White blood cell count, ×109/L

3.85 (0.1-57.1)

Aspergillosis

1

Absolute neutrophil count, ×109/L

2.1 (0-52.6)

Hemoglobin, g/dL

8 (4.1-12.6)

B-cell lymphoma

15

Platelet count, ×10 /L

43 (6-432)

T-cell lymphoma

14

Admission ferritin, mcg/L

12 308 (932-684 000)

Hodgkin lymphoma

6

Peak ferritin, mcg/L

25 736 (1412-684 000)

Myelodysplastic syndrome

4

Fibrinogen, mg/dL

186.5 (26-818)

Acute myelogenous leukemia

1

Triglycerides, mg/dL

374 (63-1984)

Acute lymphoblastic leukemia

1

Hemophagocytosis, no. of patients
(%)

83/111 (74.8%)

Metastatic prostate cancer

1

AST, U/L

169.5 (14-10 056)

HLH occurring during chemotherapy

1

ALT, U/L

10 (100-9340)

LDH, U/L

849 (15-16 020)

aPTT (seconds)

42 (15-200)

PT (seconds)

17.1 (10.1-58.3)

Sodium, mmol/L

132 (118-155)

Albumin, g/dL

2.4 (1.1-4.3)

Total bilirubin, mg/dL

1.5 (0.2-63.3)

9

Note: Abbreviations: ALT, Alanine transaminase; aPTT, activated partial
thromboplastin time; AST, Aspartate transaminase; LDH, lactate
dehydrogenase; no., number; PT, prothrombin time.

Malignancy, n = 43 (34.7%)

Autoimmune, n = 9 (7.2%)
Systemic lupus erythematosus

5

Adult-onset Still's disease

3

Juvenile rheumatoid arthritis

1

Primary immunodeficiency, n = 1
DiGeorge syndrome

1

Post solid organ transplantation, n = 2
Liver transplant
Kidney and pancreas transplant
Idiopathic, n = 24 (19.4%)

1
1
24

4
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107 (86.3%), 91 (N = 91/121; 75.2%), and 75 (60.5%), respectively.

3.4 | Outcome, 30-day mortality, and survival

Decreased fibrinogen was confirmed in 49 patients (N = 49/116;
42.2%). Prolonged PT and/or aPTT occurred in 110 (88.7%) patients.

Median duration of hospitalization was 20 days (range: 1-89 days).

Eighty-t wo (66.1%) patients were hyponatremic.

The 30-day mortality rate was 27.4% (N = 34/124); death was attrib-

There was histologic evidence of hemophagocytosis in 83/111

uted to sepsis and multiorgan failure in 24 patients, malignancy in 6,

(74.8%) patients’ bone marrow, lymph node, liver, or spleen tissues.

bleeding in 2, liver failure in 1, and unknown in 1. The median overall

Seventy-t wo out of 104 (69.2%) bone marrows showed hemophago-

survival (OS) of the entire cohort was 2.8 months (95% CI:0-6.12),

cytosis. In both institutions, soluble Il-2 receptor and NK cell activ-

with a 1-year OS of 39.2% (Figure S2).

ity assays were sent to reference laboratories. Soluble Il-2 receptor

In the univariate analysis, when comparing major clinical and

was increased in 86.1% (N = 56/65) of patients. NK cell activity was

laboratory parameters, we found that age (≥50 years), thrombocy-

decreased in 46.1% (N = 6/13) of cases, and it failed in another 4

topenia (platelet count < 40×109/L), hepatomegaly, hyponatremia

cases. Genetic testing for primary HLH was negative in all 11 tested

(sodium < 132 mmol/L), hypoalbuminemia (albumin < 2.4 g/dL), and

patients.

increasing ferritin were predictors of 30-
day mortality (Table 3).
Multivariate analysis showed that age (OR = 11.41; 95% CI:2.71-48.04;

3.2 | Ferritin trends

P = .001), hepatomegaly (OR = 15.68; 95% CI:3.24-75.96; P = .001),
hyponatremia (OR = 5.94; 95% CI:1.76-20.1; P = .004), hypoalbuminemia (OR = 7.47; 95% CI:2.08-26.85; P = .002), and increasing ferritin

On admission, ferritin was greater than 500 mcg/L in all pa-

(OR = 19.46; 95% CI:4.69-80.71; P < .001) remained significant pre-

tients with a median ferritin of 12 308 mcg/L (range: 932 mcg/L-

dictors of 30-day mortality (Table 3; Figure 1). In addition, patients

684 000 mcg/L). The median peak ferritin was 25 736 mcg/L (range:

with declining ferritin by more than 35% from the ferritin peak were

1412 mcg/L-684 000 mcg/L); the number of patients having peak

more likely to survive the first 30 days from admission (OR = 4.33; 95%

ferritin >10 000 mcg/L, >25 000 mcg/L, >50 000 mcg/L, and

CI:1.04-18.1; P = .033). Patients with increasing ferritin of more than

>100 000 mcg/L was 99 (79.8%), 63 (50.8%), 33 (26.6%), and 14

35% were more likely to die (OR = 5.67; 95% CI:1.02-31.54; P = .035).

(11.3%) patients, respectively. A decreasing ferritin trend occurred
in 85 (68.5%) patients during the first 30 days of admission.

Increasing ferritin appeared to be the most significant prognostic factor among other factors obtained at the level of multivariate
analysis. In order to better elucidate the contribution of ferritin as a

3.3 | Treatment

predictor of early mortality, we stratified our cohort into three risk
groups based on the number of risk factors obtained at the multivariate analysis: low risk defined as patients with no risk factors;

Medical management varied based on the underlying trigger for HLH

intermediate risk defined as patients with one or more risk factors

and physicians’ decisions. Patients with infection-associated HLH

excluding increasing ferritin; and high risk defined as patients with

were treated with antiviral, antibiotic, and antifungal therapies, with

increasing ferritin with or without other risk factors. Table 4 sum-

the addition of steroids in some cases. Among the 9 EBV-associated

marizes the risk groups’ stratification with their 30-day survival.

HLH, 4 patients were treated with etoposide-based regimens in-

Figure 2 shows the Kaplan-Meier survival curves of the three risk

cluding 2 patients treated with HLH-2004 protocol; the remaining

groups. Compared to intermediate-risk group patients, patients in

patients received antiviral therapy (N = 2), supportive measures

the high-risk group had greater than 4 times increased risk of early

(N = 2), and steroids (N = 1).

death (OR = 4.37; 95% CI:1.85-10.31; P = .001).

Among the 35 patients with lymphoid malignancies, 10 pa-

We investigated whether changes in ferritin occurring early

tients received etoposide-
b ased chemotherapy regimens with

during admission were predictive of early mortality. We identified

2 patients receiving rituximab. Ten patients were treated with

44 patients who had multiple ferritin measurements (at least two)

R-
C HOP or CHOP regimen (cyclophosphamide, doxorubicin,

during the 1st week of hospital admission. Multivariate analysis

vincristine, and prednisone with or without rituximab). One pa-

showed that increasing ferritin was the only significant predictor of

tient received maintenance therapy with methotrexate, one was

30-day mortality (Table S1).

treated with cyclophosphamide, two received rituximab, and one

Subgroup analysis of malignancy-associated HLH (N = 43) con-

patient was treated with cyclophosphamide and rituximab. Eight

firmed the significance of increasing ferritin as a predictor of 30-

patients were treated with steroids, and two patients received

day mortality (OR = 16.07; 95% CI:2.8-92.16; P = .001). However,

supportive care.

neither initial nor peak ferritin levels correlated with 30-
day

Nine patients with autoimmune-associated HLH received ste-

mortality.

roids alone (N = 6) or in combination with cyclosporine (N = 3).

For nonmalignancy-
associated HLH (N = 81), a peak ferri-

Idiopathic HLH cases were treated with various combinations of ste-

tin > 50 000 mcg/L was associated with 30-day mortality (OR = 3.4;

roids (N = 6), etoposide (N = 10), cyclosporine (N = 2), IVIG (N = 2),

95% CI:1.11-10.45; P = .028). Increasing ferritin correlated with 30-

or supportively (N = 4).

day mortality (OR = 4.25; 95% CI:1.42-12.76; P = .007).

|
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TA B L E 3 Univariate and multivariate analysis of predictors
of early mortality (30-day) in adult HLH . Significant p values are
shown in bold.
Parameters

Survivors

Nonsurvivors

OR
(95% CI)

P
value

Univariate analysis

3.6
(1.54-8.42)

.002

0.86
(0.38-1.95)

.71

≥50 years

36

24

<50 years

54

10

0.76
(0.35-1.69)

.51

0.92
(0.42-2.01)

.84

5.34
(2.28-
14.49)

<.001

0.70
(0.18-2.66)

.76

1.12
(0.36-3.46)

.84

2.51
(1.11-5.69)

.025

1.1
(0.49-2.46)

.82

0.86
(0.16-4.49)

1

0.95
(0.39-2.34)

.92

2.07
(0.92-4.66)

.075

Age (≥50 years)

11.41
(2.71-
48.04)

.001

Hepatomegaly

15.68
(3.24-
75.96)

.001

Hyponatremia (Na
< 132 mmol/L)

5.94
(1.76-20.1)

.004

Hypoalbuminemia
(albumin < 2.4
g/dL)

7.47 (2.08-
26.85)

.002

Ferritin change
(increase)

19.46
(4.69-
80.71)

<.001

Nonsurvivors

Admission ferritin (>10 000 mcg/L)
Yes

51

17

No

39

17

Male

55

22

Female

35

12

Caucasian

67

28

Other

23

6

(0.23-1.70)

40

13

1.29
(0.58-2.90)

.53

1.53
(0.64-3.68)

.34

Yes

47

17

No

43

17

Ferritin change (increase)

Gender

Yes

19

20

No

71

14

Coagulopathy (prolonged PT and/or aPTT)

Ethnicity
0.62

.35

Yes

79

31

No

11

3

Transaminitis (elevated AST and/or ALT)

Immunosuppression

No

P
value

Survivors

Peak ferritin (>25 000 mcg/L)

Age

Yes

OR
(95% CI)

Parameters

50

21

Yes

32

9

No

58

25

Yes

78

29

No

12

5

Hypoalbuminemia (albumin < 2.4 g/dL)

Neutropenia

Yes

38

22

No

52

12

Hyperbilirubinemia (total bilirubin > 1.2 mg/dL)

Anemia
Yes

81

31

No

9

3

0.87
(0.22-3.43)

1.0

Thrombocytopenia (Plt < 40 × 10 9/L)
Yes

33

22

No

57

12

Yes

55

20

No

35

14

Yes

80

31

No

6

2

Elevated LDH (N = 119)
3.17
(1.39-7.22)

.005

Etoposide-based treatment

Splenomegaly
Yes

62

27

No

28

7

0.57
(0.22-1.48)

.24

Yes

23

9

No

67

25

Yes

27

16

No

63

18

Associated malignancy

Hepatomegaly
Yes

17

13

No

73

21

2.66
(1.11-6.34)

.025

Multivariate analysis

Renal insufficiency
Yes

41

21

No

49

3

0.52
(0.23-1.16)

.11

2.63
(1.16-5.96)

.019

0.98
(0.37-2.64)

.98

0.81
(0.31-2.12)

.66

0.65
(0.28-1.47)

.30

0.41
(0.05-3.61)

.67

Hyponatremia (Na < 132 mmol/L)
Yes

37

22

No

53

12

Hemophagocytosis (N = 111)
Yes

62

21

No

21

7

Hypertriglyceridemia (N = 121)
Yes

66

26

No

22

7

Hypofibrinogenemia (N = 116)
Yes

33

16

No

51

16

Yes

43

13

No

8

1

Elevated sIL2R (N = 65)

(Continues)

Note: Abbreviations: ALT, Alanine transaminase; aPTT, activated partial
thromboplastin time; AST, Aspartate transaminase; LDH, lactate
dehydrogenase; Na, sodium; Plt, platelet count; PT, prothrombin time;
sIL2R, soluble IL-2 receptor.

5
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We performed the same analysis now evaluating the predictors

malignancy and hypoalbuminemia were associated with poor

of 100-day mortality. Multivariate analysis showed that age, hypo-

overall survival.14 In another study by Aulagnon et al, acute

natremia, and increasing ferritin were significant predictors of 100-

kidney injury and hematologic malignancies have been asso-

day mortality (Table S2). In addition, changes in ferritin remained the

ciated with 6-m onth mortality.15 Another report highlighting

most significant prognostic factor using the risk group stratification

infection-a ssociated HLH identified age > 50 years, persistent

approach (Table S3). Figure S3 shows the survival curves (100-day

fever of 3-d ay duration, and presence of disseminated intra-

survival) of the three risk groups.

vascular coagulation as significant indicators of mortality.16
Arca et al recognized increasing age, decreasing platelet count,
underlying lymphoma, and no etoposide in treatment as poor

4 | D I S CU S S I O N

prognostic risks for early death in a cohort of 162 adult HLH
patients.17 A recent study by Zhao and colleagues identified

In this study, we explored a large number of prognostic fac-

age ≥ 54 years, platelet count ≤ 39.5 × 10 9/L, aPTT ≥ 54 sec,

tors using multivariate analysis focusing on early mortality

triglycerides ≥ 3.23 mmol/L, LDH ≥ 1300 U/L, and malignancy

as an outcome. The 30-d ay mortality rate in our cohort was

as predictors of 30-d ay mortality in adult HLH.18 Age is one of

27.4%. Our results showed that age (≥50 years), hepatomeg-

the predictors we have identified in our study, and thrombocy-

aly, hyponatremia (sodium < 132 mmol/L), hypoalbuminemia

topenia lost significance at the multivariate level.

(albumin < 2.4 g/dL), and increasing ferritin were associ-

Similar to observations by other investigators, ferritin val-

ated with 30-d ay mortality. Parikh and colleagues found that

ues in our study were far above the 500 mcg/L cutoff set by the

(A)

(B)

(D)

(E)

(C)

F I G U R E 1 Survival curves of HLH patients with the significant prognostic risk factors of early death. (A) Age; (B) Hepatomegaly; (C)
Hyponatremia; (D) Hypoalbuminemia; (E) Ferritin change [Colour figure can be viewed at wileyonlinelibrary.com]

Risk group

a

Number of
patients

Number of
events

30-day
survival

Median 30-
day survival

Low risk

13

0

100%

Not reached

Intermediate risk

72

14

79.2%

Not reached

High risk

39

20

44.9%

27 days

Note: Low risk: zero risk factors; Intermediate risk: 1 or more risk factors excluding ferritin change;
High risk: includes ferritin change.
a

Parameters which were significant in the multivariate analysis (ie, age, hepatomegaly,
hyponatremia, hypoalbuminemia, and ferritin change) were taken as risk factors.

TA B L E 4 Summary of the three risk
groups with their 30-day survival and
median 30-day survival
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7

HLH-
2004 diagnostic criteria. Mild to moderate ferritin eleva-

regression and risk stratification that ferritin change was the most

tions are associated with many conditions, including infections,

prognostic factor of early death among the other identified risk

inflammatory disorders, and cancer. Many investigators have pro-

factors. Therefore, frequent ferritin measurements may be useful

posed higher ferritin cutoffs with varying specificities for HLH.

in predicting outcomes and in guiding physicians in risk stratifying

Our group has shown that elevated ferritin (>10 000 mcg/L) is

adult HLH patients. Other investigators have established ferritin

also not specific for pediatric or adult HLH, although its spec-

measurements as a method to evaluate response to therapy in

ificity increases with higher cutoffs.19 This ferritin cutoff was

children. Lin and colleagues followed ferritin levels in 48 pediatric

also nonspecific in diagnosing adult HLH in other studies. 20,21

HLH patients; they found that a rapid decline of ferritin levels in

Other investigators proposed ferritin levels above 30 000 μg/L

the first 3 weeks following therapy was associated with decreased

to be highly specific for HLH.

22

In addition, investigations of the

mortality. 26

prognostic value of ferritin have produced inconsistent results.
Hyperferritinemia (>50 000 mcg/L) correlated with 30-day mortality in malignancy-associated HLH. 23 Yoon and colleagues iden-

4.1 | Study limitations

tified elevated ferritin > 20 000 mcg/L to be associated with poor
survival outcomes. 24 In line with these thoughts, a recent system-

This study has several strengths, including the large number of

atic review by Sarangi and colleagues highlighted the controver-

adult HLH patients with a diverse spectrum of HLH triggers. The

sies of ferritin as a diagnostic and prognostic marker in HLH. 25

data were collected from two medical centers over a long period.

The authors concluded that the available diagnostic ferritin cutoff

Our study also has some limitations. This was a retrospective study

value of 500 mcg/L was low and clinically not relevant; thus, a re-

and dependent on case selection criteria and medical record diag-

vision of the existing guidelines considering higher ferritin cutoff

nosis coding. The possibility of data recording bias or inaccurate

values is suggested. Compared to pediatric HLH, higher ferritin

diagnoses cannot be excluded. While we might have not identi-

cutoff values (>2000 mcg/L) were predictive of adult HLH diagno-

fied some HLH diagnoses, we minimized this risk by using multi-

sis. Some studies on adult HLH have shown correlation between

ple databases in our search methodology to identify HLH cases

post-t reatment ferritin values (sometimes decline in ferritin level)

in both institutions. Patients might have been underdiagnosed if

with overall survival; however, these findings were not elucidated

some of the criteria for HLH were not routinely checked especially

by other studies.

25

the specialized referral tests (ie, soluble IL-2 receptor and NK cell

Our findings have added ferritin change as a prognostic factor

activity). Nevertheless, this study captured a large number of adult

in adult HLH. We have found that increasing ferritin during admis-

HLH patients and was able to identify new prognostic factors for

sion correlated with early death (OR = 19.46; 95% CI:4.69-8 0.71;

early death.

P < .001). In addition, patients with declining ferritin (at least 35%

Second, we used the HLH-2004 diagnostic criteria to define

decrease in ferritin) were more likely to survive while patients

adult HLH. However, these criteria may be too strict for adults with

with increasing ferritins (at least 35% increase in ferritin) were

secondary HLH and may not include some of the common clinical

more likely to die. Additionally, we have shown through logistic

and laboratory findings present in these patients. For example,
transaminitis, hypoalbuminemia, and coagulopathy were observed in
most of our patients, yet these findings are not included in the diagnostic criteria. There remains a need to refine adult HLH diagnostic
criteria by validating clinical and laboratory findings independently
in a large adult HLH cohort or registry.
Third, patients’ management may have changed over time and
between the two institutions, which could have affected our results.

5 | CO N C LU S I O N S
Physicians are diagnosing HLH with increasing frequency in adults.
Early mortality of adult HLH still represents a major challenge for
clinicians. Any delay in diagnosis or treatment initiation could be
associated with increased mortality. It would be useful to identify
subjects at high risk for early death and therefore consider early or
aggressive therapy. We examined the clinical and laboratory charF I G U R E 2 Kaplan-Meier survival curves of the three risk
groups showing 30-day survival [Colour figure can be viewed at
wileyonlinelibrary.com]

acteristics of 124 patients with adult HLH to identify risks of early
death. Our results showed that age, hepatomegaly, hyponatremia,
hypoalbuminemia, and increasing ferritin were associated with
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30-day mortality. To the best of our knowledge, this is the first study
reporting ferritin change to be a prognostic factor for early death
and, more importantly, to contribute the most to early death among
other identified risk factors. Ferritin is a cost-effective and readily
available biomarker in most clinical laboratories. Prospective studies will be necessary to determine whether frequent measurement
of ferritin is an important predictor adult HLH disease activity and
early prognosis.
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